Literature DB >> 6389142

Can chronic antidysrhythmic treatment prevent sudden death?

L M Friedman.   

Abstract

With the exception of beta-blockers, the potential benefits of chronic treatment with antidysrhythmic agents have been inadequately evaluated. Six randomized controlled clinical trials with at least 100 post-myocardial infarction in patients have been reported. The largest study had 568 patients. For total mortality, no significant difference between treatment and control was noted. Sudden cardiac death was reported in only three of the trials. The clinical trial data for patients without acute myocardial infarction are also scanty and inconclusive. Additional clinical trials of adequate sample size and appropriate design are needed in order to assess whether chronic antidysrhythmic therapy prevents sudden death.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6389142     DOI: 10.1093/eurheartj/5.suppl_b.99

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status.

Authors:  R Latini; A P Maggioni; A Cavalli
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Anti-arrhythmic properties of the alpha-adrenoceptor blocking drug indoramin.

Authors:  M A James; J V Jones
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

3.  Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes.

Authors:  H Nakaya; N Tohse; Y Takeda; M Kanno
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.